ZTS
Zoetis Inc
NYSE: ZTS · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$113.83
-2.42% today
Updated 2026-04-29
Market cap
$48.05B
P/E ratio
18.91
P/S ratio
5.08x
EPS (TTM)
$6.02
Dividend yield
1.71%
52W range
$113 – $170
Volume
3.8M
Zoetis Inc (ZTS) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.76B | $3.58B | $4.23B | $4.34B | $4.56B | $4.79B | $4.76B | $4.89B | $5.31B | $5.83B | $6.26B | $6.67B | $7.78B | $8.08B | $8.54B | $9.26B | $9.47B |
| Revenue growth (YoY) | — | +29.8% | +18.2% | +2.4% | +5.2% | +4.9% | -0.4% | +2.6% | +8.6% | +9.8% | +7.5% | +6.6% | +16.5% | +3.9% | +5.7% | +8.3% | +2.3% |
| Cost of revenue | $1.06B | $1.50B | $1.70B | $1.62B | $1.73B | $1.78B | $1.80B | $1.75B | $1.86B | $2.03B | $2.15B | $2.22B | $2.46B | $2.60B | $2.71B | $2.86B | $2.79B |
| Gross profit | $1.70B | $2.08B | $2.54B | $2.72B | $2.83B | $3.01B | $2.97B | $3.14B | $3.44B | $3.80B | $4.11B | $4.46B | $5.31B | $5.48B | $5.83B | $6.40B | $6.67B |
| Gross margin | 61.7% | 58.2% | 60.0% | 62.7% | 62.1% | 62.9% | 62.3% | 64.3% | 64.9% | 65.2% | 65.7% | 66.8% | 68.3% | 67.8% | 68.3% | 69.1% | 70.5% |
| R&D | $368.00M | $411.00M | $427.00M | $409.00M | $399.00M | $396.00M | $364.00M | $376.00M | $382.00M | $432.00M | $457.00M | $463.00M | $508.00M | $539.00M | $614.00M | $686.00M | $698.00M |
| SG&A | — | $1.79B | $1.88B | $1.33B | $1.28B | $1.38B | $1.30B | $1.20B | $1.17B | $1.32B | $1.47B | $1.49B | $1.71B | $1.72B | $1.87B | $2.02B | $2.38B |
| Operating income | $281.00M | $309.00M | $684.00M | $854.00M | $821.00M | $970.00M | $1.08B | $1.40B | $1.73B | $1.88B | $2.02B | $2.27B | $2.80B | $2.93B | $3.07B | $3.39B | $3.60B |
| Operating margin | 10.2% | 8.6% | 16.2% | 19.7% | 18.0% | 20.3% | 22.7% | 28.7% | 32.5% | 32.3% | 32.2% | 34.0% | 36.0% | 36.2% | 35.9% | 36.6% | 38.0% |
| EBITDA | $2.00M | $400.00M | $635.00M | $941.00M | $1.01B | $1.14B | $868.00M | $1.63B | $1.94B | $2.21B | $2.46B | $2.69B | $3.17B | $3.36B | $3.69B | $3.87B | $4.07B |
| EBITDA margin | 0.1% | 11.2% | 15.0% | 21.7% | 22.1% | 23.8% | 18.2% | 33.4% | 36.6% | 37.9% | 39.2% | 40.2% | 40.8% | 41.6% | 43.1% | 41.8% | 43.0% |
| EBIT | $-122.00M | $215.00M | $430.00M | $741.00M | $950.00M | $1.08B | $807.00M | $1.39B | $1.70B | $1.90B | $2.04B | $2.25B | $2.72B | $2.89B | $3.19B | $3.38B | $3.58B |
| Interest expense | $26.00M | $37.00M | $36.00M | $31.00M | $113.00M | $117.00M | $124.00M | $166.00M | $175.00M | $212.00M | $242.00M | $249.00M | $236.00M | $237.00M | $258.00M | $242.00M | $243.00M |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-100.00M | $110.00M | $245.00M | $436.00M | $504.00M | $583.00M | $339.00M | $821.00M | $864.00M | $1.43B | $1.50B | $1.64B | $2.04B | $2.11B | $2.34B | $2.49B | $2.67B |
| Net income growth (YoY) | — | +210.0% | +122.7% | +78.0% | +15.6% | +15.7% | -41.9% | +142.2% | +5.2% | +65.3% | +5.0% | +9.2% | +24.4% | +3.8% | +10.9% | +6.1% | +7.5% |
| Profit margin | -3.6% | 3.1% | 5.8% | 10.1% | 11.1% | 12.2% | 7.1% | 16.8% | 16.3% | 24.5% | 24.0% | 24.5% | 26.2% | 26.2% | 27.4% | 26.9% | 28.2% |